• 1. Dual SNAr reaction in activated ortho-halonitrobenzene: direct synthesis of substituted 1,2,3,4-tetrahydroquinoxalines, 2,3-dihydro-1,4-benzoxazines, and 1,4-benzodioxines
  Mahesh S. Deshmukh,Biswajit Das,Nidhi Jain RSC Adv. 2013 3 22389

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alkyl aryl ethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Alkyl aryl ethers

Introduction to 2,3-Dihydro-1,4-dioxino[2,3-bpyridine] (CAS No. 129421-32-5)

2,3-Dihydro-1,4-dioxino[2,3-bpyridine], identified by the Chemical Abstracts Service Number (CAS No.) 129421-32-5, is a significant compound in the field of pharmaceutical chemistry and medicinal biology. This heterocyclic compound has garnered attention due to its unique structural framework and potential applications in drug discovery and molecular research. The presence of both dioxino and pyridine moieties in its structure imparts distinct electronic and steric properties, making it a valuable scaffold for developing novel bioactive molecules.

The dioxino moiety, characterized by a oxygenated lactam ring fused with an aromatic system, contributes to the compound's reactivity and binding affinity. In contrast, the bpyridine unit introduces nitrogen-rich functionality, which is well-known for its ability to interact with biological targets such as enzymes and receptors. This combination of structural features positions 2,3-Dihydro-1,4-dioxino[2,3-bpyridine] as a promising candidate for further exploration in synthetic chemistry and pharmacological studies.

Recent advancements in computational chemistry have enabled more precise modeling of the interactions between 2,3-Dihydro-1,4-dioxino[2,3-bpyridine] and biological targets. These studies suggest that the compound exhibits favorable binding properties with certain enzymes involved in metabolic pathways relevant to inflammation and cancer. The oxygenated lactam ring has been identified as a key pharmacophore for modulating enzyme activity, while the pyridine moiety enhances solubility and bioavailability.

In parallel, experimental investigations have focused on synthesizing derivatives of 2,3-Dihydro-1,4-dioxino[2,3-bpyridine] to optimize its pharmacological profile. Researchers have explored modifications at various positions of the dioxino and pyridine rings to alter their electronic properties and improve target specificity. Preliminary results indicate that certain derivatives exhibit potent inhibitory effects on inflammatory cytokines without significant off-target effects.

The compound's potential in medicinal applications has also been supported by its stability under various conditions. Studies have demonstrated that 2,3-Dihydro-1,4-dioxino[2,3-bpyridine] maintains its structural integrity during storage and exhibits good solubility in both aqueous and organic solvents. These properties make it suitable for formulation into diverse drug delivery systems, including oral tablets and injectable solutions.

Furthermore, the synthesis of 2,3-Dihydro-1,4-dioxino[2,3-bpyridine] has been refined through modern catalytic methods that enhance yield and purity. Transition metal-catalyzed reactions have been particularly effective in constructing the dioxino-pyridine core with high efficiency. These advancements not only streamline the production process but also reduce costs associated with large-scale manufacturing.

The growing interest in 2,3-Dihydro-1,4-dioxino[2,3-bpyridine] has also spurred interdisciplinary collaborations between chemists and biologists. Such collaborations aim to bridge the gap between theoretical predictions and experimental validation of the compound's bioactivity. High-throughput screening techniques have been employed to rapidly assess the efficacy of various derivatives against a panel of disease-relevant targets.

One notable area of research involves leveraging 2,3-Dihydro-1,4-dioxino[2,3-bpyridine] as a building block for more complex drug candidates. By incorporating additional functional groups or linking it to other pharmacophores via heterocyclic bridges or amide bonds, researchers hope to develop molecules with enhanced therapeutic potential. These efforts are part of broader initiatives to address unmet medical needs through innovative chemical design.

The safety profile of 2,3-Dihydro-1,4-dioxino[2,3-bpyridine] has also been thoroughly evaluated through toxicological studies. Initial assessments suggest that the compound exhibits low toxicity at therapeutic doses when administered orally or intravenously. However， further studies are necessary to fully characterize its long-term safety implications.

Future directions for research on CAS No. 129421-32-5 include exploring its potential in treating neurological disorders such as Alzheimer's disease and Parkinson's disease. The compound's ability to cross the blood-brain barrier has made it an attractive candidate for developing neuroprotective agents. Additionally， its interaction with DNA repair enzymes has raised interest in its potential role as an anticancer therapeutic.

The development of novel synthetic methodologies for dioxino[2H]bipyridines remains a critical focus area within organic chemistry research programs worldwide。 Recent publications highlight innovative approaches using photoredox catalysis or organocatalysis to construct these challenging frameworks efficiently。 These methodologies not only expand synthetic possibilities but also contribute to fundamental understanding about reaction mechanisms involving these systems。

• 639029-34-8(3-Pyridinol,2-ethoxy-, hydrochloride (1:1))
• 1244949-25-4(3,4-Dihydro-2H-[1,4]dioxepino[2,3-b]pyridine)
• 188670-05-5(2-Ethoxypyridin-3-ol)
• 111454-85-4(Pyridine,2-butoxy-3-ethoxy-)
• 313657-94-2(2-(2-ethoxypyridin-3-yl)oxyethan-1-ol)
• 66781-24-6(1,2-Propanediol, 3-[(3-methoxy-2-pyridinyl)oxy]-)
• 1255574-40-3(2-Ethoxy-3-isobutoxypyridine)
• 1330750-22-5(2-Ethoxy-3-isopropoxypyridine)
• 1330750-35-0(2-Ethoxy-3-propoxypyridine)
• 1261365-65-4(2,3-dihydro-1,4dioxino2,3-bpyridin-7-ol)